Biotechnology

Oncology Pharma, Inc. Gives Update on Ongoing Work and Progress

October 27, 2021 12:55 PM

SAN FRANCISCO, CA / ACCESSWIRE / October 27, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Pursuant to previous communications, Oncology Pharma, Inc. (the "Company") is making progress towards pursuing its primary goal of the Co-Development plan to bring new pharmaceutical drug formulations to market with a focused approach that aims to reduce overall costs and minimize time and duration to commercialization. The Company has developed the...

Read more

Apollo Endosurgery to Report Third Quarter Financial Results on November 1, 2021

October 27, 2021 8:00 AM

AUSTIN, TX / ACCESSWIRE / October 27, 2021 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the third quarter ended September 30, 2021 on Monday, November 1, 2021 after the market closes. In conjunction with the release, Apollo will...

Read more

Puradigm Announces Kansas State University Results on Inactivation of Foodborne Diseases

October 27, 2021 8:00 AM

Study determines Puradigm COOL Air and Surface Purification technology inactivates L. monocytogenes, E.coli, and A. niger by 99% in ice machines SAN DIEGO, CA / ACCESSWIRE / October 27, 2021 / Puradigm a leading manufacturer of proactive air and surface purification technologies that have been proven to inactivate SARS-CoV-2, the virus responsible for COVID-19, and the Delta Variant, released the results of a study conducted by the Kansas State...

Read more

Itoco Provides Information About the Nopal Cactus' Ability To Act as a Key Component in Land Reclamation in Addition to Its Significant Carbon Reducing Properties

October 27, 2021 7:55 AM

TORONTO, ON / ACCESSWIRE / October 27, 2021 / ITOCO INC. (OTC PINK:ITMC) is pleased to release information about the Nopal Cactus' ability to act as a key component to land reclamation in addition to its significant carbon reducing properties. Desertification or land degradation is occurring worldwide and directly affects millions of people, especially the poor. Nopal Cactus is already widely cultivated in arid regions worldwide as a standalone...

Read more

Black Bird Biotech Announces Hiring of National Sales General Manager for MiteXstreamTM; Sales Veteran to Lead U.S. Sales and Marketing Effort

October 26, 2021 8:30 AM

FLOWER MOUND, TX / ACCESSWIRE / October 26, 2021 / Black Bird Biotech, Inc. (OTC PINK:BBBT), exclusive manufacturer and distributor of plant-based MiteXstreamTM biopesticide, announced today that it has filled its National Sales General Manager opening with the hiring of experienced sales veteran, Rich Forbis. Mr. Forbis has been charged with implementing and overseeing the company's sales and marketing strategies for MiteXstreamTM, BBBT's...

Read more

Pieris Pharmaceuticals To Host Third Quarter 2021 Investor Call and Provide Corporate Update on November 2, 2021

October 26, 2021 8:00 AM

BOSTON, MA / ACCESSWIRE / October 26, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a third quarter 2021 investor call on Tuesday, November 2, 2021 at 8:00 AM EDT to discuss financial results and provide a corporate update. To...

Read more

GenEp Raises $1.45 Million Seed Financing

October 26, 2021 7:00 AM

Financing will support development of first-in-class CNS-selective sodium channel modulators CHARLOTTESVILLE, VA / ACCESSWIRE / October 26, 2021 / GenEp, Inc., a biotechnology company developing therapies that address unmet needs in patients with epilepsy, announced today the closing of a $1.45 million seed financing. The financing was co-led by the UVA Licensing & Ventures Group Seed Fund, Angelini Lumira Biosciences Fund and 3B Future Health...

Read more

Applied UV Declares Monthly Preferred Stock Dividend

October 25, 2021 12:25 PM

MOUNT VERNON, NY / ACCESSWIRE / October 25, 2021 / Applied UV, Inc. (NasdaqCM:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced its Board of Directors has authorized the cash dividend to holders of...

Read more

M2Bio Building A World Class Supply Chain Solution - Dr. Southey and Dr. Zarrebini Update on M2Bio Blockchain and Technology Group

October 25, 2021 8:00 AM

CAPE TOWN, SA / ACCESSWIRE / October 25, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update: The M2Bio Blockchain Research & Technology Group is delighted to have completed Phase I development of the Company's Blockchain Supply Chain solution, with Phase II already underway. Using...

Read more

BioInvent Appoints Immunotherapy Expert Alexander Eggermont to Scientific Advisory Board

October 25, 2021 7:45 AM

LUND, SWEDEN / ACCESSWIRE / October 25, 2021 / BioInvent International (STO:BINV) Holds extensive expertise in surgical oncology, immunotherapy, and drug development Will provide valuable input as BioInvent further expands clinical pipeline of cancer drugs BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer...

Read more

Apollo Endosurgery Announces Positive MERIT-Trial Outcomes

October 22, 2021 4:05 PM

Trial Results Demonstrate ESG Procedure Offers Significant and Durable Weight Loss, with Improvements in Obesity-Related Health Conditions MERIT-Trial met its primary endpoints for safety and efficacy, with patients undergoing the Endoscopic Sleeve Gastroplasty (ESG) procedure achieving excess body weight loss of 49.2% at 12 months and a serious adverse event rate of 2% Patients undergoing ESG also had clinically significant reductions in...

Read more

enVVeno Medical Reports Successful Completion of First VenoValve Surgery for U.S. Pivotal Trial

October 22, 2021 9:00 AM

75 Patient Trial Underway to Evaluate Safety and Efficacy of the VenoValve as a Potential Treatment for Severe Deep Venous Chronic Venous Insufficiency (CVI) Severe CVI Impacts Approximately 2.4 million U.S. Patients with No Current Effective Treatment Options IRVINE, CA / ACCESSWIRE / October 22, 2021 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous...

Read more

ITOCO Welcomes Maria Teresa Tattersfield Yarza to Its Board of Directors and Carbon Credit Advisory Board

October 21, 2021 7:30 AM

TORONTO, ON / ACCESSWIRE / October 21, 2021 / ITOCO INC. (OTC PINK:ITMC) is pleased to welcome Maria Teresa Tattersfield Yarza to its Board of Directors. Ms. Tattersfield will be presenting to and attending the meeting session COP 26, Glasgow, UK, from 25 Oct 2021 to 12 Nov 2021. COP26 is the annual United Nations Climate Change Conference. It is the largest Conference of its type in the world. The climate talks will be the largest international...

Read more

Mosaic ImmunoEngineering Announces Upcoming Presentation at the 23rd Annual SoCalBio Conference

October 20, 2021 8:30 AM

Presentation to highlight Mosaic's naturally-derived immuno-oncology candidate, MIE-101 Intratumoral administration of MIE-101 activates immune cells to initiate potent, systemic and durable antitumor immunity NOVATO, CA / ACCESSWIRE / October 20, 2021 / Mosaic ImmunoEngineering, Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused on bridging immunology and engineering to develop novel...

Read more

Applied UV's Systems Proven to Kill Candida Auris, an Emerging Multi-Drug-Resistant Fungus

October 19, 2021 9:00 AM

Candida Auris is a pathogenic disease commonly acquired in hospitals or long-term care facilities Centers for Disease Control and Prevention ("CDC") has stated that 30-60% of people with C. auris bloodstream infections die CDC currently considers Candidiasis as one of the most significant infectious diseases in the world today. Currently, there is no vaccine or preventative measures taken for C. auris for humans Growing global scientific...

Read more

Edesa Biotech Reports Favorable Mortality Reductions in COVID-19 Study

October 19, 2021 8:00 AM

Mortality reductions demonstrated across multiple patient groups Additional efficacy signals recorded in a broad range of mild to severe ARDS patients Company to focus on critically ill population for Phase 3 TORONTO, ON / ACCESSWIRE / October 19, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced additional results from the Phase 2 part of an...

Read more

From Chronic to Curable? RHEACELL is Developing a Novel Cell-Therapy Agent for the Treatment of Chronic Venous Ulcers

October 19, 2021 3:30 AM

HEIDELBERG, GERMANY / ACCESSWIRE / October 19, 2021 / Heidelberg-based biopharmaceutical company is conducting a follow-up study with highly purified stem cells (AMESANAR (R) ) for the treatment of previously incurable chronic ulcers. Heidelberg, 19. October 2021 - More than 80,000 people in Germany suffer from chronic venous ulcers (CVU). Triggered by venous insufficiency, wounds and weeping ulcers can develop that may not heal for years....

Read more

Dermata Announces Positive Results from Phase 1b Clinical Trial of DMT310 for the Treatment of Mild-to-Moderate Psoriasis

October 18, 2021 4:01 PM

- DMT310 achieved a PGA score of 0 or 1 for the target lesion in 29.6% of patients at Week 8 - - DMT310 demonstrated a total PASI score of 0 or 1 for the target lesion in 25.9% of patients at Week 8 - - DMT310 demonstrated a 19.6% reduction from baseline in pruritus at Week 8 - - Phase 1b results support further investigation of DMT310 in psoriasis - SAN DIEGO, CA / ACCESSWIRE / October 18, 2021 / Dermata Therapeutics, Inc. ("Dermata" or the...

Read more

dievini Explains Reasons for Changes in Shareholdings In CureVac Due To Legal Restructuring and Obligations Under a Share Program

October 18, 2021 2:10 AM

WALLDORF, GERMANY / ACCESSWIRE / October 18, 2021 / dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), a holding company of SAP co-founder Dietmar Hopp with an investment focus on innovative biotechnology companies, announced today that it and certain related parties filed on October 15, 2021, with the United States Securities and Exchange Commission an amendment to its Schedule 13D with respect to the common shares of CureVac. The...

Read more

Hemogenyx Pharmaceuticals PLC Announces Lease of New York Mink Building Custom Laboratory

October 18, 2021 2:00 AM

LONDON, UK / ACCESSWIRE / October 18, 2021 / Hemogenyx Pharmaceuticals has signed a lease with The Janus Property Company ("Janus") for a new custom-designed and built laboratory in the Mink Building, located in the Manhattanville Factory District of New York, adjacent to Columbia University and City College. The Company's new 10,000 rentable square feet lab will include two clean rooms purpose-built by Janus, allowing it to pursue...

Read more